Specialty-backup


Glenmark’s specialty business is focused on identifying products and formulations that fulfill unique and unmet medical needs for physician specialists who treat a range of conditions, with our initial efforts focused on respiratory and dermatology. Specialty assets are being commercialized by Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding, SA.

Specialty Respiratory Pipeline

Molecule
Proposed Indication(s)/Indication(s)
MoA/Class
Pre-CLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVAL
RESPIRATORY
RYALTRIS™ (olopatadine hydrochloride and mometasone furoate) Nasal Spray 665 mcg/25mcg*
Seasonal Allergic Rhinitis
Steroid + antihistamine
Seasonal Allergic Rhinitis
Steroid + antihistamine
PHASE 3
GSP 304
COPD
LAMA
COPD
LAMA
Phase 2
GBR 310
Ashthma/CIU
Biosimilar
Ashthma/CIU
Biosimilar
Phase 1
GRC 39815
COPD
RORyt inhibitor
COPD
RORyt inhibitor
Pre-CLINICAL
*Also known as GSP 301 Nasal Spray

Specialty Dermatology Products

 

Ecoza Prescribing Information

 

Recedo Prescribing Information

 

US Medical Information, Pharmacovigilance, and Quality Assurance:

To receive medical information or to report a product complaint or side effect (also called an adverse event), please contact Glenmark’s Global Customer Service Center at:
GlobalCustomerService@glenmarkpharma.com or at 1-888-721-7115 ( 7:00 a.m. – 9:00 p.m., EST.